Yin‐Hsun Feng

Chi Mei Medical Center — Taiwan

Medicine · Health Sciences

25h-index3.4kcitations107works21.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(17), Colorectal Cancer Treatments and Studies(10), Fibroblast Growth Factor Research(8), Advanced Breast Cancer Therapies(8), Lung Cancer Treatments and Mutations(7)

Publications106 total

Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma
Journal of the Formosan Medical Association·2025· 2 citedOpen Access
ORAL ABSTRACT: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-1497: Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Clinical Lymphoma Myeloma & Leukemia·2025· 3 cited
POSTER: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Clinical Lymphoma Myeloma & Leukemia·2025
The mediating effect of resourcefulness between self-management efficacy and cancer-related fatigue in advanced cancer patients
Chinese Journal of Integrative Nursing·2025Open Access
Frequent association of malignant effusions in plasmablastic lymphoma: a single-institutional experience of nine cases in Taiwan
Blood Research·2025· 3 citedOpen Access
Long-term survival outcomes of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma.
Journal of Clinical Oncology·2025· 2 cited
Improving the Thrombocytopenia Adverse Reaction of Belinostat Using Human Serum Albumin Nanoparticles
International Journal of Nanomedicine·2024· 2 citedOpen Access
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
BMC Cancer·2024· 12 citedOpen Access
Exploring neuron-specific steroid synthesis and DHEAS therapy in Alzheimer's disease
The Journal of Steroid Biochemistry and Molecular Biology·2024· 3 cited
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and <i>FGFR</i> alterations: Pooled analysis of RAGNAR and LUC2001 studies.
Journal of Clinical Oncology·2024· 3 cited
Tu1578 IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS (PTS) WITH MAIN TRUNK AND/OR CONTRALATERAL PORTAL VEIN INVASION (VP4) TREATED WITH ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN A PH III STUDY
Gastroenterology·2024
Abstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
Cancer Research·2024· 5 cited
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Journal of Clinical Oncology·2024· 52 citedOpen Access
Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle‐invasive bladder cancer
Cancer Medicine·2024· 6 citedOpen Access
Mitochondrial Mechanisms in Temozolomide Resistance: Unraveling the Complex Interplay and Therapeutic Strategies in Glioblastoma
Mitochondrion·2023· 15 cited
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
2023· 2 citedOpen Access
Indolent EBV-positive T-cell lymphoma of the gastrointestinal tract with metachronous lesions involved by different neoplastic clones
Pathology·2023· 1 citedOpen Access
1032P A phase II study of sintilimab plus IBI310 for Epstein-Barr virus (EBV)-associated gastric cancer
Annals of Oncology·2023· 2 citedOpen Access
Risk Predictors for Mortality in Inpatients with Cancer and Coronavirus Disease 2019 during the Omicron Wave
Journal of Cancer Research and Practice·2023· 1 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Chao‐Jung Tsao(7), Ann‐Lii Cheng(7), Yee Chao(6), Chia‐Jui Yen(6), Wen‐Tsung Huang(6), Wei‐Ting Chang(6), Shukui Qin(5), Baek‐Yeol Ryoo(5), Ho Yeong Lim(5), Ai‐Li Shiau(5), Chao‐Liang Wu(5), Zhih‐Cherng Chen(5), Sung‐Bae Kim(4), Joon Oh Park(4), Wu‐Chou Su(4), Do‐Youn Oh(4), Yoon Sim Yap(3), Ghassan K. Abou‐Alfa(3), Debashis Sarker(3), John S. Bomalaski(3)